Company: PTHS
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001753926-25-001561
Chunk: 10

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-29
Form: 424B3
Chunk 10
---
 should not consider information on our website to be part of this information statement.

Pelthos makes available free of charge under the “Investors” section of our website all of our filings with the SEC including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on our website as soon as reasonably practicable after Pelthos electronically files or furnishes, as applicable, the information with the SEC.

Additional informationabout us is included in documents incorporated by reference in this prospectus. See “Where You Can Find More Information” and “Information Incorporated by Reference.”

<div align='center'>6

RISK FACTORS</div>

Investing in our securities involves significant risk. The prospectus supplement applicable to each offering of our securities will contain a discussionof the risks applicable to an investment in our securities. Prior to investing in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in this prospectus and any applicable prospectus supplement, and in the documents incorporated by reference herein, including Channel’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and any other filings we make with the SEC under the Exchange Act that are incorporated by reference together with all of the other information contained or incorporated by reference herein or therein. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

Risks Related to Our Financial Position and Capital Needs

The report of the independent registered public accounting firm on our 2024 and 2023 financial statements contains a going concern qualification.

The report of the independent registered
public accounting firm covering our consolidated financial statements for the years ended December 31, 2024 and 2023 stated that
certain factors, including that we have suffered recurring losses from operations and have an accumulated deficit at December 31,
2024, raised substantial doubt as to our ability to continue as a going concern. Because we are not yet producing sufficient revenue
to sustain our operating costs, we are dependent upon raising capital to continue our business. If we are unable to raise capital,
we may be unable to continue as a going concern.

We have incurred significant losses since our inception. We expect